87572-47-2

Basic information

• Product Name: N^α-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-N^ε-<(phenylmethoxy)carbonyl>-(S)-lysine
• Synonyms: N^α-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-N^ε-<(phenylmethoxy)carbonyl>-(S)-lysine
• CAS NO: 87572-47-2
• Molecular Weight: 470.566
• Mol File: 87572-47-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N^α-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-N^ε-<(phenylmethoxy)carbonyl>-(S)-lysine(CAS DataBase Reference)
• NIST Chemistry Reference: N^α-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-N^ε-<(phenylmethoxy)carbonyl>-(S)-lysine(87572-47-2)
• EPA Substance Registry System: N^α-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-N^ε-<(phenylmethoxy)carbonyl>-(S)-lysine(87572-47-2)

Safety Data

• Hazardous Substances Data: 87572-47-2(Hazardous Substances Data)

Upstream product

• 63628-63-7 Nε-benzyloxycarbonyl-L-lysine tert-butyl ester 
• 82586-61-6 ethyl 2-bromo-4-phenylbutanoate 
• 93836-41-0 N^α-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-N^ε-<(phenylmethoxy)carbonyl>-(S)-lysine tert-butyl ester 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 
• 64920-29-2 2-oxo-4-phenylbutanoic acid ethyl ester 

Downstream Products

• 135793-15-6 (3S)-2-{(S)-2-[(S)-1-(ETHOXYCARBONYL)3-PHENYLPROPYLAMINO]-6-(BENZYLOXYCARBONYLAMINO)HEXANOYL}-3-CARBAMOYL-2-AZABICYCLO-[2.2.2]OCTANE 
• 121142-14-1 7-α-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-N^ε-<(phenylmethoxy)carbonyl>-(S)-lysyl>-1,4-dithia-7-azaspiro<4.4>nonane-8(S)-carboxylic acid benzyl ester 

Relevant articles and documents

Angiotensin Converting Enzyme Inhibitors: Spirapril and Related Compounds

The synthesis of spirapril (5), spiraprilat (25), their RSS stereoisomers, and their glycyl (18b) and lysyl (36, 37) analogues is described.These compounds were evaluated in vivo for inhibition of angiotensin converting enzyme (ACE), and selected compounds were evaluated for in vitro ACE inhibition (spirapril ID50 16 μg/kg; spiraprilat IC50 0.8 nM, ID50 8 μg/kg).In anesthetized rats, iv, esters 5 and 36 are more potent than enalapril, and diacids 25 and 37 are more potent than enalaprilat in vitro.In the conscious rats, orally, 5 and enalapril (2) showed potent and sustained activity at doses of 0.03-1 and 0.1-1 mg/kg, respectively.From this work, spirapril was selected for clinical evaluation as an antihypertensive agent.